Table 3.
Distribution of SSA treatment strategies, by treatment line and primary tumor location
| Treatment | First line, n (%) | Second line, n (%) | Third line, n (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic | Midgut | Other | Pancreatic | Midgut | Other | Pancreatic | Midgut | Other | |
| (n = 180) | (n = 258) | (n = 159) | (n = 122) | (n = 116) | (n = 89) | (n = 74) | (n = 55) | (n = 55) | |
| All treatmentsa | |||||||||
| SSA | 125 (69.4) | 249 (96.5) | 122 (76.7) | 95 (77.9) | 112 (96.6) | 70 (78.7) | 64 (86.5) | 52 (94.5) | 43 (78.2) |
| Cytotoxic therapies | 48 (26.7) | —b | 39 (24.5) | 49 (40.2) | 15 (12.9) | 35 (39.3) | 29 (39.2) | 13 (23.6) | 20 (36.4) |
| Sunitinib | — | — | — | 15 (12.3) | — | — | 19 (25.7) | 0 (0) | — |
| Everolimus | — | 0 (0) | — | 16 (13.1) | — | — | — | — | — |
| Interferon | — | 6 (2.3) | — | — | 15 (12.9) | — | — | — | — |
| Investigational therapies | 30 (16.7) | — | 13 (8.2) | 38 (31.1) | 72 (62.1) | 37 (41.6) | 21 (28.4) | 31 (56.4) | 21 (38.2) |
| Other | — | — | — | 0 (0) | — | — | 0 (0) | 0 (0) | — |
| Detailed treatment regimens | |||||||||
| SSA monotherapy | 82 (45.6) | 234 (90.7) | 100 (62.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| SSA in combination | 43 (23.9) | 15 (5.8) | 22 (13.8) | 95 (77.9) | 112 (96.6) | 70 (78.7) | 64 (86.5) | 52 (94.5) | 43 (78.2) |
| Cytotoxic therapies | 18 (10) | — | 14 (8.8) | 38 (31.1) | 14 (12.1) | 21 (23.6) | 25 (33.8) | 12 (21.8) | 15 (27.3) |
| Sunitinib | — | — | — | — | — | — | 19 (25.7) | 0 (0) | — |
| Everolimus | — | 0 (0) | — | 12 (9.8) | — | — | — | — | — |
| Interferon | — | — | — | — | 14 (12.1) | — | — | — | — |
| Investigational therapies | 12 (6.7) | — | — | 30 (24.6) | 70 (60.3) | 34 (38.2) | 16 (21.6) | 29 (52.7) | 17 (30.9) |
| Other | — | 0 (0) | — | 0 (0) | — | — | 0 (0) | 0 (0) | — |
| Non‐SSA therapies only | 55 (30.6) | — | 37 (23.3) | 27 (22.1) | — | 19 (21.3) | — | — | 12 (21.8) |
| Cytotoxic therapy | 30 (16.7) | — | 25 (15.7) | — | — | 14 (15.7) | — | — | — |
| Sunitinib | — | 0 (0) | 0 (0) | — | 0 (0) | — | 0 (0) | 0 (0) | — |
| Everolimus | — | 0 (0) | — | — | 0 (0) | — | — | 0 (0) | — |
| Interferon | 0 (0) | — | — | 0 (0) | — | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Investigational therapies | 18 (10) | — | — | — | — | — | — | — | — |
| Other | 0 (0) | — | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
a
All treatments initiated within the line are reported, and total may add up to >100%.
b
Fewer than five patients in this category. For confidentiality reasons, they are masked in the table.
Abbreviation: SSA, somatostatin analog.